Cadmore media player playing video Boston and Bioprocessing: GEN Reports Live from the First Day at BPI
Video Player
Accessibility
Using forms mode, you can utilize keyboard shortcuts to make usability more efficient.
Space bar will play and pause the video. Pressing escape will close all displays and pressing it again will jump to the end of the player.
You can press A to open the Keyboard Shortcut Dialog which also provides an audio description of the player and all of its features.
Language
1x
Play Speed
Adjust Volume
Transcript
Search
Result Count
of
Click to jump to result
Search
Re-center
Segments
Result Count
of
Click to jump to result
Search
Name:
Boston and Bioprocessing: GEN Reports Live from the First Day at BPI
Description:
Boston and Bioprocessing: GEN Reports Live from the First Day at BPI
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/07b4f8bc-da4e-4377-9cd9-6c07c15b31d8/videoscrubberimages/Scrubber_3.jpg?sv=2019-02-02&sr=c&sig=XPbOqZC%2Fegust%2FjK4nFiZ69jq%2B95gpbSKAEn9rTUbJI%3D&st=2025-01-15T13%3A44%3A46Z&se=2025-01-15T17%3A49%3A46Z&sp=r
Duration:
T00H10M02S
Embed URL:
https://stream.cadmore.media/player/07b4f8bc-da4e-4377-9cd9-6c07c15b31d8
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/07b4f8bc-da4e-4377-9cd9-6c07c15b31d8/GEN_BPI.mp4?sv=2019-02-02&sr=c&sig=JS%2B2djxGuTuh6IdEtN%2BuNAWdOazlYeNth9tQyHxT2Cg%3D&st=2025-01-15T13%3A44%3A47Z&se=2025-01-15T15%3A49%3A47Z&sp=r
Upload Date:
2023-10-19T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
KEVIN: Hi, everyone. It's the J&J show. It's John Sterling and Julianna LeMieux at BPI, which I've just learned stands for Bio Process International. They're on the road in Boston. GEN's two most senior and distinguished editors John Sterling, editor-in-chief, Julianna LeMieux, deputy editor. Hello, guys, how are things?
JOHN STERLING: Hey, Kevin.
JULIANNA LEMIEUX: Hi, Kevin.
JOHN STERLING: Boston's a wonderful town.
KEVIN: [LAUGHS]
JOHN STERLING: Always is.
KEVIN: We know that. John, I know you've been a regular attendee at BPI for many years. Do you even dare to hazard how long you've been going to this show?
JOHN STERLING: I have a vague-- it's retreating into the mist of years gone by. But for years, it's been the biggest show we attend every year. Obviously, the two things that have changed, well, three things actually. One, there are more people. Two, there are more exhibitors. Three, there are more technologies to talk about. And actually, the fourth, there's more talks going on, more presentations both in conference rooms, on the floor.
JOHN STERLING: And the traffic here has just been amazing.
KEVIN: Yeah.
JOHN STERLING: This is the first which are usually the strongest.
KEVIN: This is the, would you say, the biggest, most important single event in the bioprocessing event calendar?
JOHN STERLING: Yes, yeah, I don't know how long it takes them to plan out but the conferences are all-- the topics are always so well thought out.
KEVIN: Yeah.
JOHN STERLING: They get the top people from industry, not just manufacturers, but also people in places like Biogen and Bristol-Myers Squibb. I went to one of the sessions that somebody gave from there yesterday on how complex biologics are getting, which is affecting manufacturers. So [INAUDIBLE] everybody who has anything to do with therapeutics manufacturing and even some students who are learning how to be bioprocessors.
KEVIN: Julianna, this is your first BPI. So how does this compare? You go to all the fun shows like AGBT and SynBioBeta, these cool, trendy technology shows. What's your first impression of BPI like?
JULIANNA LEMIEUX: Yeah, I mean the conference itself is enormous. The amount of content is way more than one person could ever take in. It's-- they have different tracks. And so I've just-- I just kind of picked a track and stayed with that. And it was mostly focused on gene therapy. So that's what I've been doing today. That's been really great day.
JULIANNA LEMIEUX: Learning about bioprocessing is fascinating. It's so essential to so many of the stories that we write about at I and all of the technology that is put into. It's just been a great world to dive into and learn more about.
JOHN STERLING: Yeah, and picking up on what Julianna said, for years, I've had to explain to people that as essential and as critical as you can get, and from the moment you discover molecule till the end, obviously, R&D is where people use the term sexy. That's where all the new drugs come with all the excitement. Well, if these molecules and drugs cannot be produced economically, and efficiently, and safely, everything comes before that is for naught.
JOHN STERLING: Just a quick example, when I started back years ago coming here, I believe the cost of a biotherapeutic, the final cost was related to 60%-- 60% of the cost of downstream processing is related to the cost of activity. Today, I'm not sure what it is. I think somewhere between 10% and 20%. Maybe one of the viewers who sees it can call in and say, what that is now.
JOHN STERLING: But that's been a big change.
KEVIN: Yeah.
JULIANNA LEMIEUX: Yeah, and also there's so many challenges, Kevin. I mean, it's so-- what they are working on, these problems are so hard, and so fundamentally important, and also drives so many of the other issues that we talk about as well, like the cost as John was saying, access to patients, all of those different things. It's just all wrapped up in the talks that we're hearing today.
KEVIN: Yeah, so today's only been day one. But what-- are there any major overarching themes that you are anticipating or you know the organizers are planning to showcase during the course of the event this week?
JOHN STERLING: I think Julianna and I have really-- we've seen some of the same, some are different because we've gone to different sessions. I mentioned before how complex biologics are getting. Something from Bristol-Myers Squibb talked about that. Of course, there's a lot on-- we've got before mRNA, there was a panel session yesterday, in fact. Four different people talking about what are the issues, what are the obstacles, what do you have to look out for to make sure you're producing a safe product.
JOHN STERLING: Today, somebody from Repligen gave a real interesting talk, the evolution of manufacturing from monoclonals to viral vectors to gene therapy. Gene therapy, as Julianna said, is very predominant here. It's predominant every day. Where we work, we hear about it. So there was that talk this morning. There was another talk yesterday on gene therapy, actually, the development and engineering to produce adenoviral vector production.
JOHN STERLING: And so today was something on exosomes. So the gamut of anything that has to do with a bio therapeutic is covered here, some a little more than others.
JULIANNA LEMIEUX: I would have had that same list, honestly. I've been in talks with all those different subjects.
KEVIN: What about the companies? As you've-- I know the exhibit floor only just opened about 20 minutes ago, but who stands out? Who's really trying to make a splash?
JOHN STERLING: If you--
JULIANNA LEMIEUX: Yeah--
JOHN STERLING: Well, if you saw some of the booths here, they're all trying to make a splash.
KEVIN: OK.
JOHN STERLING: I mean, these are expensive. But yeah, no, all the big players are here.
KEVIN: Yeah.
JOHN STERLING: We plan on seeing them today and tomorrow.
KEVIN: Yeah.
JOHN STERLING: Don't want to mention anyone in specific to leave anybody out because they're all here. But what's interesting, a number of them are giving presentations. And many of them are here on the floor to talk, and that's what's interesting really to me, the latest advances in equipment. That was a big topic in the Repligen talk this morning about the evolution of monoclonals to gene therapy.
JULIANNA LEMIEUX: And you know what is another thing that I've been hearing, and I think we'll hear more of tomorrow. I was going to say we might be able to answer the company question better tomorrow after because, as you said, the expo-- we just got here and so everybody's kind of just settling in. But also the collaborations that are going on between the drug makers and the manufacturing, that came up in several of the talks I was in.
JULIANNA LEMIEUX: They're really-- they're not just making something and passing it off anymore to be manufactured. They are like in the same meetings. They're working together, integrated. And so that's another theme that, I think, I found very interesting and I think I'll keep my ears open for it.
JOHN STERLING: Yeah, and in some cases, not just with drug companies, its association with other vendors who are probably not competitive with what they're doing. The pieces, after so many years-- I've been covering the field for 39 years-- so many pieces are starting to come together. And I think over the next five years, we're going to see things that once we thought were science fiction.
KEVIN: Yeah, and, John, of course, bioprocessing has been and remains a very important pillar in the coverage that GEN offers in the magazine and online. So presumably, you'll be picking up some good leads for stories that will be featuring in the magazine throughout 2024.
JOHN STERLING: Yeah, exactly, especially the two things. One, they'll take older systems and just really up them, change them because they work, and they just make them work better. And then, of course, there's going to be a slew of new instruments introduced here. Again, the session I went to this morning on, I think, Repligen alone, I think, has 3 on its side. And I'm sure all the other vendors will have the same. I mean, this is big chance for them.
JOHN STERLING: It's like a coming out party for them and their new products. And this is the big biotech debutante show. [INAUDIBLE]
KEVIN: Right. Right. So guys, what's on tap for the rest of the week apart from a really slap up north end dinner tonight, I presume?
JOHN STERLING: Well--
JULIANNA LEMIEUX: The first thing on tap is to get a cup of coffee because it's, mid-afternoon and we've been going all day.
JOHN STERLING: Yeah, I know nothing about the north end of Boston so thank you for telling us that. No, even though I've been here, yeah, I just come here and do what I have to do and just leave. But yeah, it's going to be great dinner tonight.
JULIANNA LEMIEUX: They have Italian food there.
JOHN STERLING: Oh, that's my favorite. And we have the whole commercial team here, which is really cool, because it just gives not just the editorial but gives GEN really good representation here. And again, what we're going to be doing the next few days visiting some companies we know about, as I said before. My question has been forever what have you have new? Why should my readers and viewers be interested in what you have to offer in terms of their research, either upgraded or something new.
JOHN STERLING: And that's what we come here for because our job is to service our readers.
KEVIN: Well, John, and, Julianna, we look forward to catching up with you tomorrow, same place, same time, and review of your first ever North end dinner. I find that hard to believe. But have a great evening and enjoy the rest of the show. We'll catch up with you soon.
JOHN STERLING: And look for the dinner review in the next issue of GEN.
KEVIN: Exactly. All right.
JULIANNA LEMIEUX: Bye.
KEVIN: Bye.
JOHN STERLING: Bye-bye.
Segment:0 .
KEVIN: Hi, everyone. It's the J&J show. It's John Sterling and Julianna LeMieux at BPI, which I've just learned stands for Bio Process International. They're on the road in Boston. GEN's two most senior and distinguished editors John Sterling, editor-in-chief, Julianna LeMieux, deputy editor. Hello, guys, how are things?
JOHN STERLING: Hey, Kevin.
JULIANNA LEMIEUX: Hi, Kevin.
JOHN STERLING: Boston's a wonderful town.
KEVIN: [LAUGHS]
JOHN STERLING: Always is.
KEVIN: We know that. John, I know you've been a regular attendee at BPI for many years. Do you even dare to hazard how long you've been going to this show?
JOHN STERLING: I have a vague-- it's retreating into the mist of years gone by. But for years, it's been the biggest show we attend every year. Obviously, the two things that have changed, well, three things actually. One, there are more people. Two, there are more exhibitors. Three, there are more technologies to talk about. And actually, the fourth, there's more talks going on, more presentations both in conference rooms, on the floor.
JOHN STERLING: And the traffic here has just been amazing.
KEVIN: Yeah.
JOHN STERLING: This is the first which are usually the strongest.
KEVIN: This is the, would you say, the biggest, most important single event in the bioprocessing event calendar?
JOHN STERLING: Yes, yeah, I don't know how long it takes them to plan out but the conferences are all-- the topics are always so well thought out.
KEVIN: Yeah.
JOHN STERLING: They get the top people from industry, not just manufacturers, but also people in places like Biogen and Bristol-Myers Squibb. I went to one of the sessions that somebody gave from there yesterday on how complex biologics are getting, which is affecting manufacturers. So [INAUDIBLE] everybody who has anything to do with therapeutics manufacturing and even some students who are learning how to be bioprocessors.
KEVIN: Julianna, this is your first BPI. So how does this compare? You go to all the fun shows like AGBT and SynBioBeta, these cool, trendy technology shows. What's your first impression of BPI like?
JULIANNA LEMIEUX: Yeah, I mean the conference itself is enormous. The amount of content is way more than one person could ever take in. It's-- they have different tracks. And so I've just-- I just kind of picked a track and stayed with that. And it was mostly focused on gene therapy. So that's what I've been doing today. That's been really great day.
JULIANNA LEMIEUX: Learning about bioprocessing is fascinating. It's so essential to so many of the stories that we write about at I and all of the technology that is put into. It's just been a great world to dive into and learn more about.
JOHN STERLING: Yeah, and picking up on what Julianna said, for years, I've had to explain to people that as essential and as critical as you can get, and from the moment you discover molecule till the end, obviously, R&D is where people use the term sexy. That's where all the new drugs come with all the excitement. Well, if these molecules and drugs cannot be produced economically, and efficiently, and safely, everything comes before that is for naught.
JOHN STERLING: Just a quick example, when I started back years ago coming here, I believe the cost of a biotherapeutic, the final cost was related to 60%-- 60% of the cost of downstream processing is related to the cost of activity. Today, I'm not sure what it is. I think somewhere between 10% and 20%. Maybe one of the viewers who sees it can call in and say, what that is now.
JOHN STERLING: But that's been a big change.
KEVIN: Yeah.
JULIANNA LEMIEUX: Yeah, and also there's so many challenges, Kevin. I mean, it's so-- what they are working on, these problems are so hard, and so fundamentally important, and also drives so many of the other issues that we talk about as well, like the cost as John was saying, access to patients, all of those different things. It's just all wrapped up in the talks that we're hearing today.
KEVIN: Yeah, so today's only been day one. But what-- are there any major overarching themes that you are anticipating or you know the organizers are planning to showcase during the course of the event this week?
JOHN STERLING: I think Julianna and I have really-- we've seen some of the same, some are different because we've gone to different sessions. I mentioned before how complex biologics are getting. Something from Bristol-Myers Squibb talked about that. Of course, there's a lot on-- we've got before mRNA, there was a panel session yesterday, in fact. Four different people talking about what are the issues, what are the obstacles, what do you have to look out for to make sure you're producing a safe product.
JOHN STERLING: Today, somebody from Repligen gave a real interesting talk, the evolution of manufacturing from monoclonals to viral vectors to gene therapy. Gene therapy, as Julianna said, is very predominant here. It's predominant every day. Where we work, we hear about it. So there was that talk this morning. There was another talk yesterday on gene therapy, actually, the development and engineering to produce adenoviral vector production.
JOHN STERLING: And so today was something on exosomes. So the gamut of anything that has to do with a bio therapeutic is covered here, some a little more than others.
JULIANNA LEMIEUX: I would have had that same list, honestly. I've been in talks with all those different subjects.
KEVIN: What about the companies? As you've-- I know the exhibit floor only just opened about 20 minutes ago, but who stands out? Who's really trying to make a splash?
JOHN STERLING: If you--
JULIANNA LEMIEUX: Yeah--
JOHN STERLING: Well, if you saw some of the booths here, they're all trying to make a splash.
KEVIN: OK.
JOHN STERLING: I mean, these are expensive. But yeah, no, all the big players are here.
KEVIN: Yeah.
JOHN STERLING: We plan on seeing them today and tomorrow.
KEVIN: Yeah.
JOHN STERLING: Don't want to mention anyone in specific to leave anybody out because they're all here. But what's interesting, a number of them are giving presentations. And many of them are here on the floor to talk, and that's what's interesting really to me, the latest advances in equipment. That was a big topic in the Repligen talk this morning about the evolution of monoclonals to gene therapy.
JULIANNA LEMIEUX: And you know what is another thing that I've been hearing, and I think we'll hear more of tomorrow. I was going to say we might be able to answer the company question better tomorrow after because, as you said, the expo-- we just got here and so everybody's kind of just settling in. But also the collaborations that are going on between the drug makers and the manufacturing, that came up in several of the talks I was in.
JULIANNA LEMIEUX: They're really-- they're not just making something and passing it off anymore to be manufactured. They are like in the same meetings. They're working together, integrated. And so that's another theme that, I think, I found very interesting and I think I'll keep my ears open for it.
JOHN STERLING: Yeah, and in some cases, not just with drug companies, its association with other vendors who are probably not competitive with what they're doing. The pieces, after so many years-- I've been covering the field for 39 years-- so many pieces are starting to come together. And I think over the next five years, we're going to see things that once we thought were science fiction.
KEVIN: Yeah, and, John, of course, bioprocessing has been and remains a very important pillar in the coverage that GEN offers in the magazine and online. So presumably, you'll be picking up some good leads for stories that will be featuring in the magazine throughout 2024.
JOHN STERLING: Yeah, exactly, especially the two things. One, they'll take older systems and just really up them, change them because they work, and they just make them work better. And then, of course, there's going to be a slew of new instruments introduced here. Again, the session I went to this morning on, I think, Repligen alone, I think, has 3 on its side. And I'm sure all the other vendors will have the same. I mean, this is big chance for them.
JOHN STERLING: It's like a coming out party for them and their new products. And this is the big biotech debutante show. [INAUDIBLE]
KEVIN: Right. Right. So guys, what's on tap for the rest of the week apart from a really slap up north end dinner tonight, I presume?
JOHN STERLING: Well--
JULIANNA LEMIEUX: The first thing on tap is to get a cup of coffee because it's, mid-afternoon and we've been going all day.
JOHN STERLING: Yeah, I know nothing about the north end of Boston so thank you for telling us that. No, even though I've been here, yeah, I just come here and do what I have to do and just leave. But yeah, it's going to be great dinner tonight.
JULIANNA LEMIEUX: They have Italian food there.
JOHN STERLING: Oh, that's my favorite. And we have the whole commercial team here, which is really cool, because it just gives not just the editorial but gives GEN really good representation here. And again, what we're going to be doing the next few days visiting some companies we know about, as I said before. My question has been forever what have you have new? Why should my readers and viewers be interested in what you have to offer in terms of their research, either upgraded or something new.
JOHN STERLING: And that's what we come here for because our job is to service our readers.
KEVIN: Well, John, and, Julianna, we look forward to catching up with you tomorrow, same place, same time, and review of your first ever North end dinner. I find that hard to believe. But have a great evening and enjoy the rest of the show. We'll catch up with you soon.
JOHN STERLING: And look for the dinner review in the next issue of GEN.
KEVIN: Exactly. All right.
JULIANNA LEMIEUX: Bye.
KEVIN: Bye.
JOHN STERLING: Bye-bye.
Form Title Download
Transcript
Form Title Bookmark
Entire Media
Segment(s)
Custom Clip
Start At:
End At:
Form Title Share
Entire Media
Segment(s)
Custom Clip
Start At:
End At:
Form Title Accessibility and Keyboard Shortcuts
The cadmore media player is a professional video and audio player experience designed to deliver media as well as relevant transcript, segmentation, and metadata. On the screen is a traditional html video player with buttons such as play, pause, forward, captioning, language and play speed selection and more. Adjacent to the video player are generally tabs, one of which shows a scrolling transcript of the video and the other shows any segmentation of the media, sometimes referred to as chapters. At the top of the video is a menu bar containing an Explore button and Tools button. The Explore button allows you to dig deeper into the video by opening up an explore dialog which contains tabs for a visual navigation of the video using thumbnails, an about tab which contains rich metadata about the media, a segments tab which contains further information about the video, and a related tab which contains links to other media related to this media. The tools button opens a menu with options for sharing the media on social media, creating bookmarking links, creating embed codes for your website, generating citations, and more.
Keyboard Shortcuts
Keyboard shortcuts only work while you are in forms mode. By entering forms mode, you will be able to quickly access portions of the media player with single key commands.
Spacebar: Play/Pause Toggle
I: Info Menu,
O: Tools Menu
T: Transcript Tab,
S: Segments Tab
F: Forward 15,
R: Rewind 15
L: Languages,
P: Playspeed
M: Mute Toggle,
V: Volume Bar
N: Video Only Toggle,
B: Full Screen Toggle
C: Captions Toggle
Escape: Closes dialogs and menus / Exits Player
Z: Next Transcript Chapter
X: Previous Transcript Chapter
Q: Next Transcript Paragraph
W: Previous Transcript Paragraph
Entire Media
Segment(s)
Custom Clip
Start At:
End At:
Embed Size
-
You Size - Responsive
-
We Size - Responsive
-
Picture Overlay Popup
-
400 x 225
-
512 x 288
-
400 x 700
-
768 x 1024
-
1024 x 512
-
1280 x 608
Form Title Cite
No citation provided.
Info
Segments
Related
Thumbnails
Exit Clip Mode
You have requested to see a portion of the video outside of the clip.
Click OK to switch to the full video or click if you would like to stay inside the clip. You can always go back to the clip with Tools and Clip Mode